How have MATN shares performed in 2024?

Mateon Therapeutics' stock was trading at $0.0383 at the beginning of 2024. Since then, MATN shares have increased by 7.2% and is now trading at $0.0410. View the best growth stocks for 2024 here .

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics, Inc. (OTCMKTS:MATN) released its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02).

What other stocks do shareholders of Mateon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mateon Therapeutics investors own include Amarin (AMRN) , Cyclacel Pharmaceuticals (CYCC) , Oramed Pharmaceuticals (ORMP) , Synergy Pharmaceuticals (SGYP) , VIVUS (VVUS) , Idera Pharmaceuticals (IDRA) , Ascent Solar Technologies (ASTI) , BioDelivery Sciences International (BDSI) and Avid Bioservices (CDMO) .

How do I buy shares of Mateon Therapeutics?

Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:MATN

Mateon Therapeutics (MATN) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free MATN Stock Alerts

$0.04

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.04
▼
$0.04
50-Day Range: $0.03
▼
$0.05
52-Week Range: $0.13
▼
$0.38

Volume: 25,025 shs
Average Volume: 338,444 shs
Market Capitalization: $3.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials SEC Filings

Get Mateon Therapeutics alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Mateon Therapeutics Stock (OTCMKTS:MATN)

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

MATN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MATN Stock News Headlines

February 27, 2024 | wsj.com

Viking Therapeutics Inc.

February 25, 2023 | benzinga.com

Sorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News Summary

See More Headlines

Receive MATN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2019
Today: 4/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:MATN
Previous Symbol: NASDAQ:MATN
CUSIP: N/A
CIK: 908259
Web: www.mateon.com
Phone: 650-635-7000
Fax: N/A
Employees: 13
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -64.66%
Return on Assets: -42.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.17
Quick Ratio: 0.17

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 90,240,000
Free Float: N/A
Market Cap: $3.70 million
Optionable: Not Optionable
Beta: 1.33

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Vuong Trieu (Age 58)
Chairman & CEO
Comp: $166.53k
Mr. Amit Shah (Age 54)
Chief Financial Officer
Comp: $66.5k
Dr. Chulho Park Ph.D. (Age 54)
Chief Technology Officer
Comp: $129.86k
Dr. Larn Hwang (Age 58)
Chief Scientific Officer
Dr. Anthony E. Maida III (Age 69)
M.A., M.B.A., MA, MBA, Ph.D., Chief Clinical Officer of Translational Medicine & Director
Dr. Seymore Howard Fein (Age 72)
Chief Medical Officer
Mr. Saranjit Saund
CBO & GM of AI Division
Mr. Burcak Beser
CTO of AI Division

Key Competitors

View All Competitors

MATN Stock Analysis - Frequently Asked Questions

How have MATN shares performed in 2024?: Mateon Therapeutics' stock was trading at $0.0383 at the beginning of 2024. Since then, MATN shares have increased by 7.2% and is now trading at $0.0410.
View the best growth stocks for 2024 here.
How were Mateon Therapeutics' earnings last quarter?: Mateon Therapeutics, Inc. (OTCMKTS:MATN) released its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02).
What other stocks do shareholders of Mateon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Oramed Pharmaceuticals (ORMP), Synergy Pharmaceuticals (SGYP), VIVUS (VVUS), Idera Pharmaceuticals (IDRA), Ascent Solar Technologies (ASTI), BioDelivery Sciences International (BDSI) and Avid Bioservices (CDMO).
How do I buy shares of Mateon Therapeutics?: Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MATN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial